Navigation Links
Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th
Date:10/24/2007

IRVINE, Calif., Oct. 24 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (OTC: CGCP), announced that the company will release results for its third quarter ended September 30, 2007 prior to market open on Wednesday, November 14, 2007. The company also said that President Richard P. Lanigan and Senior Vice President and Chief Financial Officer William R. Abbott will host an investor conference call that day at 12:00 p.m. Eastern time (9:00 a.m. Pacific time) to review the company's financial results and business outlook.

The call is open to all interested investors through a live audio web broadcast via the Internet at http://www.cardiogenesis.com and will also be available by dialing (888) 873-4896. The participant passcode is 14418507. The call will be archived on the company's web site and will be available for playback for seven days beginning shortly after the live webcast.

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis. The company's market leading Holmium: YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease. Surgical products and accessories for the company's minimally invasive Percutaneous Myocardial Channeling (PMC) procedure are currently being marketed in Europe and other international markets.

For more information on the company and its products, please visit the Cardiogenesis company website at http://www.cardiogenesis.com or the direct to patient website at http://www.heartofnewlife.com.

Cardiogenesis Corporation, +1-949-420-1800 http://www.cardiogenesis.com


'/>"/>
SOURCE Cardiogenesis Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
11. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... effects and diminished effectiveness over time. A recent study published in STEM CELLS ... by stimulating subventricular zone (SVZ) stem cells to produce more neural cells. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Executive search firm, ... Avomeen Analytical Services. Harvill is a distinguished life sciences expert with a proven ... a leader in a wide range of services related to laboratory testing and ...
(Date:3/27/2017)... , March 27, 2017 Infectex Ltd., a Russian portfolio company ... clinical study of SQ109 added to the standard drug therapy regimen in patients with ... at Sequella, Inc. ( USA ) and the US National Institutes of ... ... Maxwell Biotech Venture Fund Logo ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... method to engineer scalable and customizable vascular grafts in JoVE’s Video Journal, the ... lead to new and improved ways of treating coronary artery disease (CAD). Lam ...
Breaking Biology Technology:
(Date:2/27/2017)... 27, 2017   Strategic Cyber Ventures , the ... led a $3.5 million investment in  Polarity , the ... Ventures is DC based and is led by cybersecurity ... . Ron Gula , also a longtime cybersecurity ... in this series A round of funding. This new ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):